Tanmay Bhat on GLP-1 Drugs Failing Appetite Suppression & Genetic Report
GLP-1 drugs not working for appetite suppression? Comedian and content creator Tanmay Bhat has sparked important conversations by sharing his personal experience with GLP-1 medications. Widely used for type 2 diabetes and weight management, these drugs like semaglutide and tirzepatide didn't deliver the expected appetite reduction for him, leading him to investigate genetic factors.
Tanmay Bhat's Experience with GLP-1 Medications
In a candid post on X (formerly Twitter), Tanmay Bhat revealed that despite trying GLP-1 receptor agonists, he experienced zero appetite suppression. "Anybody here who's fu**in around with GLP1's experienced zero appetite suppression? I have experienced zero appetite suppression," he wrote. He pointed to his genetic report as a potential explanation: "Upon further investigation, my gene report suggested a BDNF gene variant that is prone to weakened satiety signalling. Anybody here an expert on this matter?"
Bhat didn't stop there. He explored solutions, mentioning a proposed combination therapy: "Another proposed solution that I read was combining Tirz with Cagrilinitide. Unable to find a trustworthy source for Cagri. Any leads would be appreciated." He also sought recommendations for reliable peptide sources in India.
"Chill yaar, I've lost over 75 kilos without touching a single GLP1 injection. But I like all new health tech and I am dabbling with GLP1s to see how I feel about it. I workout, I eat well, I have consistent blood works for the last 5 years. I have great guidance, I know what I'm doing. Spare me moral lecture pls."
Responding to critics who suggested sticking to lifestyle changes alone, Bhat defended his approach by highlighting his impressive 75 kg weight loss history without medications. His posts drew varied responses—some shared similar non-responder experiences, while others offered advice.
Understanding GLP-1 Receptor Agonists: How They Work
GLP-1 receptor agonists, including semaglutide (found in Ozempic and Wegovy) and tirzepatide (in Mounjaro and Zepbound), are FDA-approved for regulating blood sugar in type 2 diabetes. They mimic the glucagon-like peptide-1 hormone, which:
- Slows gastric emptying to promote fullness.
- Reduces appetite by signaling the brain's satiety centers.
- Improves insulin secretion and lowers glucagon levels.
These mechanisms make them popular for weight loss, with many users reporting significant reductions in calorie intake. However, as Bhat's story shows, not everyone responds equally.
BDNF Gene Variant and Satiety Signaling
The brain-derived neurotrophic factor (BDNF) gene plays a role in brain health, neuroplasticity, and appetite regulation. Variants in BDNF can impair satiety signaling pathways, potentially explaining why some individuals like Bhat see no appetite changes from GLP-1 drugs. This genetic factor influences how the brain processes fullness signals from the gut, even when medications target GLP-1 receptors.
Why GLP-1 Drugs May Not Suppress Appetite in Some People
Medical experts, including those at the Cleveland Clinic, emphasize that GLP-1 medications' effectiveness varies. Here are key reasons some experience zero appetite suppression:
Dose and Adjustment Period
These drugs start at low doses (e.g., 0.25 mg semaglutide weekly) and titrate up over weeks or months. Full appetite effects may not appear until higher doses, requiring patience. Rushing can lead to side effects without benefits.
